Tonix Pharmaceuticals Holding Corp. (TNXP) - NASDAQ
  • Mon, May 9, 7:15 AM
    | Mon, May 9, 7:15 AM
  • Fri, Mar. 4, 7:36 AM
    • Tonix Pharmaceuticals (TNXP) Q4 results: Revenues: $0; R&D Expense: $9.5M (+63.8%); SG&A: $3.9M (+21.9%); Net Loss: ($13.4M) (-48.9%); Loss Per Share: ($0.71) (+14.5%).
    • FY2015 results: Revenues: $0; R&D Expense: $35.5M (+90.9%); SG&A: $12.7M (+41.1%); Net Loss: ($48.1M) (-74.3%); Loss Per Share: ($2.86) (-3.2%); Quick Assets: $43M (+12.6%).
    • No guidance given.
    | Fri, Mar. 4, 7:36 AM | 12 Comments
  • Fri, Mar. 4, 7:02 AM
    | Fri, Mar. 4, 7:02 AM
  • Nov. 9, 2015, 9:08 AM
    • Tonix Pharmaceuticals (NASDAQ:TNXP): Q3 EPS of -$0.72 misses by $0.10.
    | Nov. 9, 2015, 9:08 AM
  • Aug. 10, 2015, 7:17 AM
    • Tonix Pharmaceuticals (NASDAQ:TNXP): Q2 EPS of -$0.73 misses by $0.08.
    | Aug. 10, 2015, 7:17 AM
  • May 11, 2015, 6:54 AM
    • Tonix Pharmaceuticals (TNXP -0.5%) Q1 results: Revenues: $0; R&D Expense: $6.8M (+88.9%); SG&A: $2.9M (+81.3%); Net Loss: ($9.7M) (-86.5%); Loss Per Share: ($0.71) (-20.3%); Quick Assets: $58.2M (+52.4%).
    • No guidance given.
    | May 11, 2015, 6:54 AM
  • May 11, 2015, 6:09 AM
    • Tonix Pharmaceuticals (NASDAQ:TNXP): Q1 EPS of -$0.71 misses by $0.17.
    | May 11, 2015, 6:09 AM
  • Mar. 3, 2015, 8:49 AM
    • Tonix Pharmaceuticals (TNXP) Q4 results: Revenues: $0; R&D Expense: $5.8M (+346.2%); SG&A: $3.2M (+33.3%); Net Loss: ($9M) (-143.2%); Loss Per Share: ($0.83) (-29.7%).
    • FY2014 results: Revenues: $0; R&D Expense: $18.6M (+295.7%); SG&A: $9M (+45.2%); Net Loss: ($27.6M) (-153.2%); Loss Per Share: ($2.77) (+17.8%); Quick Assets: $38.2M (+365.9%).
    • No guidance given.
    | Mar. 3, 2015, 8:49 AM | 3 Comments
  • Mar. 3, 2015, 8:12 AM
    • Tonix Pharmaceuticals (NASDAQ:TNXP): Q4 EPS of -$0.83 misses by $0.02.
    | Mar. 3, 2015, 8:12 AM
  • Nov. 10, 2014, 12:49 PM
    • Tonix Pharmaceuticals (TNXP -3.1%) Q3 results: Revenue: $0; Net Loss: ($7.4M) (-138.7%); Loss Per Share: ($0.71) (+18.4%); Quick Assets: $46.2M (+463.4%).
    • No guidance given.
    | Nov. 10, 2014, 12:49 PM
  • Nov. 10, 2014, 8:54 AM
    • Tonix Pharmaceuticals (NASDAQ:TNXP): Q3 EPS of -$0.71 misses by $0.02.
    | Nov. 10, 2014, 8:54 AM
  • Aug. 8, 2014, 4:33 PM
    • Tonix Pharmaceuticals Holding (TNXP +9.3%) Q2 results: Revenues: $0; Net Loss: ($6.0M) (-189.7%); Loss Per Share: ($0.61) (+35.8%); Quick Assets: $43.9M (+435.4%).
    • No financial guidance given.
    | Aug. 8, 2014, 4:33 PM | 5 Comments
Company Description
Tonix Pharmaceuticals Holding Corp. is a pharmaceutical company. It is engaged in developing and manufacturing new pharmaceutical products that are used in central nervous system drugs in large and growing markets. It products include TNX-102 SL and TNX-201. Tonix Pharmaceuticals Holding was... More
Sector: Healthcare
Industry: Drug Manufacturers - Major
Country: United States